Letter to the EditorBeneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
Graphical abstract
Keywords
Cited by (0)
Collaborators. Vieri Vannucchi MD, Division of Internal Medicine, Azienda USL Toscana Centro, S.Maria Nuova Hospital, Florence; Monica Todoerti, MD, Rheumatology Unit, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Massimiliano Parodi, MD, Rheumatology Unit, AO SS. Antonio e Biagio e C. Arrigo, Alessandria, Paola Rossi, MD, Rheumatology Unit, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Piero Davio, MD, Internal Medicine Department, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Pinuccia Omodeo, MD, Pulmonary Diseases Department, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Guido Chichino, MD, Infectious Diseases Department, AO SS. Antonio e Biagio e C. Arrigo, Alessandria, Ernesto Cristiano Lauritano, MD, Emergency Department, AO SS. Antonio e Biagio e C. Arrigo, Alessandria; Antonio Maconi, IRFI Infrastructure Research, Education, Innovation, AO SS. Antonio e Biagio e C. Arrigo – Alessandria; Anna Maria Di Carlo, Consultant, Division of Internal Medicine, Azienda Ospedaliera Ospedali RiunitiMarche Nord, Fano; Rita Girolimetti, Consultant, Division of Internal Medicine, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro; Chiara Pelosi, Consultant, Division of Internal Medicine, Hospital of Ariano Irpino, Avellino; Annamaria Bellizzi, Consultant, Division of Internal Medicine, Hospital of Ariano Irpino, Avellino; Luca Franco, Division of Internal Medicine, Hospital of Ariano Irpino, Avellino; Italy
ClinicalTrials.gov Identifier: NCT04358614.